Cargando…

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs

Objective: We conducted a meta-analysis to assess the efficacy and safety of mirabegron (50 mg/day) and antimuscarinics in treating ureteral stent-related symptoms (SRSs). Methods: All randomized controlled trials (RCTs) were identified by searching PubMed, Embase, Web of Science, and Cochrane Libra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Youyi, Li, Qi, Zou, Qingsong, Cui, Yuanshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618993/ https://www.ncbi.nlm.nih.gov/pubmed/37920205 http://dx.doi.org/10.3389/fphar.2023.1266636

Ejemplares similares

High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment
por: Liao, Chun-Hou, et al.
Publicado: (2016)

PRISMA-combined α-blockers and antimuscarinics for ureteral stent-related symptoms: A meta-analysis
por: Zhang, Yu-ming, et al.
Publicado: (2017)

The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis
por: Zhang, Dongxu, et al.
Publicado: (2021)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

The efficacy and safety of antimuscarinics for the prevention or treatment of catheter-related bladder discomfort: a systematic review and meta-analysis of randomized controlled trials
por: Zhou, Zhongbao, et al.
Publicado: (2021)

Distal end of Double-J ureteral stent position on ureteral stent-related symptoms: A systematic review and meta-analysis
por: Bao, Xingjun, et al.
Publicado: (2022)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
por: Johnson, Theodore M., et al.
Publicado: (2022)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

Long-Term Efficacy of Mirabegron Add-On Therapy to Antimuscarinic Agents in Patients With Spinal Cord Injury
por: Han, Seok-Hee, et al.
Publicado: (2019)

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
por: Carlson, Kevin V., et al.
Publicado: (2021)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
por: Kuo, Yuh-Chen, et al.
Publicado: (2021)

Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
por: Yamanishi, Tomonori, et al.
Publicado: (2020)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
por: Nazir, Jameel, et al.
Publicado: (2018)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

The Efficacy of Mirabegron in Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis
por: Cai, Dawei, et al.
Publicado: (2022)

Meta-Analysis of the Efficacy and Safety of Ketamine on Postoperative Catheter-Related Bladder Discomfort
por: Lu, Youyi, et al.
Publicado: (2022)

Comparison of ureteral stent diameters on ureteral stent-related symptoms: A systematic review and meta-analysis
por: Diatmika, Anak Agung Ngurah Oka, et al.
Publicado: (2022)

A randomized controlled trial study on effectiveness between tadalafil versus combination mirabegron and solifenacin on treatment of ureteral stent-related symptoms
por: Ciayadi, Tjia Adynata, et al.
Publicado: (2023)

Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)
por: Carlson, Kevin V., et al.
Publicado: (2019)

Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
por: Hoffman, Veena, et al.
Publicado: (2021)

Mirabegron attenuates porcine ureteral contractility via α1-adrenoceptor antagonism
por: Lim, Iris, et al.
Publicado: (2022)

The efficacy and safety of silodosin for the treatment of ureteral stones: a systematic review and meta-analysis
por: Yang, Diandong, et al.
Publicado: (2016)

Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs
por: Sun, Xifeng, et al.
Publicado: (2018)

Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial
por: Khullar, Vik, et al.
Publicado: (2013)

Impact of loop-tail ureteral stents on ureteral stent-related symptoms immediately after ureteroscopic lithotripsy: Comparison with pigtail ureteral stents
por: Taguchi, Makoto, et al.
Publicado: (2017)

Use of Antimuscarinics in the Elderly
por: Patel, Bhavin, et al.
Publicado: (2009)

Advances in Drug Delivery via Biodegradable Ureteral Stent for the Treatment of Upper Tract Urothelial Carcinoma
por: Shan, Hongli, et al.
Publicado: (2020)

Pooled analysis of efficacy and safety of ureteral stent removal using an extraction string
por: Sun, Xujie, et al.
Publicado: (2019)

Impact of Ureteral Stent Material on Stent-related Symptoms: A Systematic Review of the Literature
por: Boeykens, Matthias, et al.
Publicado: (2022)

Meta-analysis of the efficacy of sexual intercourse for distal ureteric stones
por: Xu, Bin, et al.
Publicado: (2019)

Concentration-dependent alpha(1)-Adrenoceptor Antagonism and Inhibition of Neurogenic Smooth Muscle Contraction by Mirabegron in the Human Prostate
por: Huang, Ru, et al.
Publicado: (2021)

Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach
por: Kessler, Thomas M., et al.
Publicado: (2011)

Ureterosciatic hernia treated with ureteral stent placement
por: Nakazawa, Yusuke, et al.
Publicado: (2018)

A systematic review of magnetic versus conventional ureteric stents for short term ureteric stenting
por: Lyons, Louise, et al.
Publicado: (2022)

Solifenacin/Mirabegron Induces an Acute Compliance Increase in the Filling Phase of the Capacity-Reduced Urinary Bladder: A Pressure-Volume Analysis in Rats
por: Peng, Hsien-Yu, et al.
Publicado: (2021)

Urinary incontinence: Not a typical ureteric stent symptom
por: Nesbitt, Alexander L.
Publicado: (2018)

Translation and Validation of the Ureteral Stent Symptoms Questionnaire in Urdu
por: Mirani, Kaleem K, et al.
Publicado: (2022)

Cardiovascular safety of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study
por: Katoh, Takao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vbsmft6jrlrgmqdfhhflk9b8og